EyeGate receives FDA approval to initiate PRK pivotal study
By Akshay Kedari  Date: 2019-06-04

EyeGate receives FDA approval to initiate PRK pivotal study

EyeGate Pharmaceuticals, Inc. has reportedly received approval from the U.S. Food and Drug Administration to start photorefractive keratectomy or PRK pivotal study.

As per trusted sources, the FDA has determined that EyeGate provided adequate data to support the initiation of the clinical study and has asked the pharma company to make some alterations in the patient informed consent document before enrollment. Sources claim that the company will immediately address these changes and looks forward to enrollments starting this month.

Sources familiar with the knowledge of the matter cite Stephen From, Chief Executive Officer of EyeGate, to have said in a statement that the company is extremely pleased with the comments received from the FDA about the design of the company’s PRK pivotal study and plans to initiate enrollment at the earliest.

The company expects topline outcomes by the end of 2019, anticipating them to be positive, so that the de novo application for commercialization can be submitted soon, From claimed, adding that post the successful approval, the company’s OGB platform will be the United States’ foremost prescription Hyaluronic Acid eyedrop formulation presenting a huge opportunity for the company.

According to a reliable news report, EyeGate Pharmaceuticals Inc. stock spiked 20% as of June 3. The company’s stock has reportedly climbed $0.05 from the earlier closing price of $0.25 on a volume of 3,160,386 stocks.

For the record, EyeGate is a clinical-stage specialty pharmacological company dedicated to developing and commercializing drugs and therapeutics through its two proprietary platform technologies focused on the treatment of eye diseases and disorders.

The company’s OBG platform formed on a crosslinked thiolated CMHA-S, a modified form of the natural polymer hyaluronic acid, which is a gel that holds unique physical and chemical features such as hydrating and healing properties when applied to the ocular surface, reported sources. 

Source Credit
https://finance.yahoo.com/news/eyegate-receives-approval-fda-initiate-105500530.html

https://www.investorsobserver.com/market-intelligence-center/stock-update/is-eyegate-pharmaceuticals-eyeg-stock-a-strong-buy-following-fda-study-approval/


 

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Toyota bets big on a new mode of local transportation: flying taxis
Toyota bets big on a new mode of local transportation: flying taxis
By Akshay Kedari

A California-based aerospace company, Joby Aviation recently announced that it raised USD 590 million as venture capital in a series C round of funding led by Toyota motor company. A sizeable investment made by the automaker in the round is a signifi...

Scandit and Samsung partner to optimize barcode scanning performance
Scandit and Samsung partner to optimize barcode scanning performance
By Akshay Kedari

Software company Scandit AG announced that it will specifically update its range of barcode scanning software for the Samsung Galaxy XCover Pro. The integration of optimized barcode scanning software of Scandit and Samsung’s latest ruggedized a...

Twitter announces new feature to give users more control over replies
Twitter announces new feature to give users more control over replies
By Akshay Kedari

Twitter is finally addressing the issues that have plagued the social network for a while now. The company has reportedly confirmed that it will be testing new features that would allow users to have control over who can reply over their tweets and h...

Faulty sunroofs force Daimler to recall Mercedes-Benz vehicles in U.S.
Faulty sunroofs force Daimler to recall Mercedes-Benz vehicles in U.S.
By Akshay Kedari

The sunroof glass panel can possibly detach itself and pose a major hazard Mercedes-Benz USA could pay $7M if it does not comply with previous settlement terms Daimler AG, the German carmaker, announced that it shall recall about 744,000 Mercede...

Lilly wins Alimta Vitamin Regimen Patent Lawsuit against Apotex Inc
Lilly wins Alimta Vitamin Regimen Patent Lawsuit against Apotex Inc
By Akshay Kedari

  Ruling by the US District Court has concluded that Apotex Inc. would be infringing the Alimta vitamin regimen patent by launching its proposed products until the patent expiration of Lilly   The ruling would bar Apotex from marketing...